Literature DB >> 22793170

Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience.

Dan P Zandberg1, Franklin Hendrick, Emily Vannorsdall, Jason Bierenbaum, Michael L Tidwell, Yi Ning, Xianfeng Frank Zhao, Amy J Davidoff, Maria R Baer.   

Abstract

Little is known about disparities in myelodysplastic syndromes (MDS). We performed a retrospective chart review of patients with MDS (n = 252) evaluated at the University of Maryland Greenebaum Cancer Center between 2000 and 2010. The median age at diagnosis was 65 years, which was lower than the median age of 76 years for patients with MDS in the Surveillance, Epidemiology and End Results database. Black males were younger than white males (62 vs. 68 years; p = 0.03) and had longer time to referral (9 vs. 1.5 months; p = 0.03), but black and white females did not differ in age or in time to referral. A difference in World Health Organization subtype classification was noted in black and white patients at diagnosis, but not at referral. There was no difference between all other pretreatment characteristics, treatment and survival by race. Our data suggest barriers to tertiary care referral for older patients and for black males.

Entities:  

Mesh:

Year:  2012        PMID: 22793170     DOI: 10.3109/10428194.2012.710904

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; Steven D Gore; Donald M Stablein; Nancy DiFronzo; Gregory A Abel; Amy E DeZern; Jesse D Troy; Dana E Rollison; John W Thomas; Myron A Waclawiw; Jane Jijun Liu; Tareq Al Baghdadi; Matthew J Walter; Rafael Bejar; Edward J Gorak; Daniel T Starczynowski; James M Foran; James R Cerhan; Lynn C Moscinski; Rami S Komrokji; H Joachim Deeg; Pearlie K Epling-Burnette
Journal:  Leuk Lymphoma       Date:  2019-05-21

Review 2.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

3.  Epidemiologic study of myelodysplastic syndromes in a multiethnic, inner city cohort.

Authors:  Ashwin Sridharan; Rishi Jain; Marcus A Bachhuber; Yiting Yu; Kh Ramesh; Krishna Gundabolu; Ellen W Friedman; Amit K Verma
Journal:  Exp Hematol Oncol       Date:  2014-08-23

4.  The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population-based study.

Authors:  Xingnong Ye; Dan Chen; Yan Zheng; Cai Wu; Xiaoqiong Zhu; Jian Huang
Journal:  Hematol Oncol       Date:  2019-09-06       Impact factor: 5.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.